logo
Share SHARE
FONT-SIZE Plus   Neg

AVEO Oncology: FDA Panel To Review Tivozanib For Treatment Of Advanced RCC

AVEO Oncology (AVEO) and Astellas Pharma Global Development Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced Wednesday that the U.S. Food and Drug Administration's or FDA Oncologic Drugs Advisory Committee or ODAC will review the company's New Drug Application or NDA for tivozanib for the treatment of patients with advanced renal cell carcinoma or RCC during the morning session of its meeting on May 2, 2013.

ODAC reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer, and makes recommendations to the Commissioner of Food and Drugs. According to the timelines established by the Prescription Drug User Fee Act or PDUFA, the review of the NDA is expected to be complete by July 28, 2013.

In November 2012, AVEO and Astellas announced that the FDA accepted for filing the NDA for tivozanib with the proposed indication for the treatment of patients with advanced RCC. The NDA includes results of the global Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) trial, a randomized superiority-designed pivotal trial evaluating the efficacy and safety of tivozanib compared to sorafenib, an approved targeted agent, in 517 patients with advanced RCC, as well as data from 16 additional AVEO-sponsored studies involving over 1,000 subjects who received tivozanib. Tivozanib is an investigational medicine and is not currently approved in any country.

Advanced RCC, or kidney cancer, is the ninth most commonly diagnosed cancer in men and women in the U.S.1 Worldwide it is estimated that more than 250,000 people are diagnosed and more than 100,000 people die from the disease each year.2 RCC accounts for more than 90 percent of all kidney cancers.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Albertsons Cos., a major grocer, announced that it is buying meal kit company Plated, reportedly marking the first acquisition of a prepared-meals company by a national grocery chain. As per reports, the New York-based Plated, which does business as DineInFresh Inc., would be purchased for an estimated $175 to $200 million. Liliane Bettencourt, the heiress to French cosmetics giant L'Oreal, has died aged 94, her family said Thursday. She was the daughter of Eugène Schueller, founder of the L'Oréal Group. Bettencourt was considered the world's richest woman by both Forbes and the Bloomberg Billionaire Index. Her net worth was estimated at around $44 billion. CVS Pharmacy will limit opioid prescriptions to a seven-day supply for certain conditions, as part of its efforts to fight the national opioid abuse epidemic. CVS Caremark plans to roll out opioid utilization control initiatives for all commercial, health plan, employer and Medicaid clients as of February 1, 2018 unless the client chooses to opt out.
comments powered by Disqus
Follow RTT